0000899243-21-039333.txt : 20211005
0000899243-21-039333.hdr.sgml : 20211005
20211005194744
ACCESSION NUMBER: 0000899243-21-039333
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211005
FILED AS OF DATE: 20211005
DATE AS OF CHANGE: 20211005
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Shannon John Patrick Jr
CENTRAL INDEX KEY: 0001553595
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40880
FILM NUMBER: 211308411
MAIL ADDRESS:
STREET 1: DURATA THERAPEUTICS, INC.
STREET 2: 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR
CITY: MORRISTOWN
STATE: NJ
ZIP: 07960
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Xeris Biopharma Holdings, Inc.
CENTRAL INDEX KEY: 0001867096
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 180 N. LASALLE STREET, SUITE 1600
CITY: CHICAGO
STATE: IL
ZIP: 60601
BUSINESS PHONE: 844-445-5704
MAIL ADDRESS:
STREET 1: 180 N. LASALLE STREET, SUITE 1600
CITY: CHICAGO
STATE: IL
ZIP: 60601
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-10-05
0
0001867096
Xeris Biopharma Holdings, Inc.
XERS
0001553595
Shannon John Patrick Jr
C/O XERIS BIOPHARMA HOLDINGS, INC.
180 N. LASALLE STREET, SUITE 1600
CHICAGO
IL
60601
0
1
0
0
See Remarks
Common Stock
2021-10-05
4
A
0
70496
A
70496
D
Common Stock
2021-10-05
4
A
0
193333
A
263829
D
Stock Option (Right to Buy)
1.55
2021-10-05
4
A
0
160335
A
2027-02-03
Common Stock
160335
160335
D
Stock Option (Right to Buy)
1.55
2021-10-05
4
A
0
25136
A
2027-06-11
Common Stock
25136
25136
D
Stock Option (Right to Buy)
5.93
2021-10-05
4
A
0
28072
A
2028-01-31
Common Stock
28072
28072
D
Stock Option (Right to Buy)
12.50
2021-10-05
4
A
0
34977
A
2028-05-15
Common Stock
34977
34977
D
Stock Option (Right to Buy)
13.88
2021-10-05
4
A
0
80000
A
2029-01-31
Common Stock
80000
80000
D
Stock Option (Right to Buy)
3.94
2021-10-05
4
A
0
100000
A
2030-08-18
Common Stock
100000
100000
D
On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among Xeris Pharmaceuticals, Inc. ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), the Issuer ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction").
(Continued from Footnote 1) At the effective time of the Merger (the "Merger Effective Time"), all existing shares of Xeris common stock (the "Xeris common stock") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of HoldCo common stock received upon vesting of Xeris restricted stock units that were vested as of the Merger Effective Time, net of shares withheld for tax.
Represents restricted stock units each representing a contingent right to receive one share of HoldCo common stock (the "HoldCo RSU"). At the Merger Effective Time, each restricted stock unit representing a contingent right to acquire one share of Xeris common stock (the "Xeris RSU") that was outstanding immediately prior to the Merger Effective Time was automatically converted into a HoldCo RSU on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU.
At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option.
These options are fully vested as of the date hereof.
25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months.
These options are early exercisable.
President and Chief Operating Officer
/s/ Beth Hecht, as Attorney-in-Fact
2021-10-05